| Suspended | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer NCT07136493 | City of Hope Medical Center | N/A |
| Recruiting | AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRI NCT06708910 | Heinrich-Heine University, Duesseldorf | — |
| Active Not Recruiting | Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer NCT06868758 | Chongqing General Hospital | — |
| Enrolling By Invitation | Validation of TAD in HER-2 with More Than 2 Lymph Nodes NCT06821490 | Fundación para la Investigación del Hospital Clínico de Valencia | — |
| Recruiting | RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study NCT07030569 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Recruiting | Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk NCT06557057 | Mayo Clinic | — |
| Active Not Recruiting | Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer NCT05710328 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and P NCT04108858 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Br NCT04457596 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Nipple Aspirate Fluid in Detecting Breast Cancer NCT03715959 | Ohio State University Comprehensive Cancer Center | N/A |
| Withdrawn | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer NCT04351230 | Academic and Community Cancer Research United | Phase 2 |
| Terminated | Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients Wit NCT04249622 | Mayo Clinic | Phase 2 |
| Recruiting | Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer NCT04517838 | Mayo Clinic | — |
| Suspended | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer NCT04120246 | Veana Therapeutics | Phase 1 |
| Active Not Recruiting | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer NCT03368729 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Unknown | A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Posit NCT03908749 | Anhui Provincial Hospital | — |
| Terminated | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 NCT03630809 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer NCT03530696 | University of Arizona | Phase 2 |
| Active Not Recruiting | HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer NCT03387553 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Unknown | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or NCT03500380 | RemeGen Co., Ltd. | Phase 2 / Phase 3 |
| Active Not Recruiting | Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer NCT03384914 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients W NCT03364348 | George W. Sledge Jr. | Phase 1 |
| Active Not Recruiting | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast NCT03179904 | Mayo Clinic | Phase 2 |
| Recruiting | Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuva NCT02945579 | M.D. Anderson Cancer Center | N/A |
| Completed | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer NCT02673398 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breas NCT02827877 | City of Hope Medical Center | Phase 2 |
| Completed | Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Sur NCT02654119 | University of Nebraska | Phase 2 |
| Completed | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients NCT02003209 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Pa NCT01622868 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated NCT00684983 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cance NCT00390455 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With NCT00005970 | National Cancer Institute (NCI) | Phase 3 |